New gene therapy injection shows promise for tough leukemia

NCT ID NCT07246707

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new gene therapy called KSV01 for patients with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The study will enroll 30 adults aged 18 to 80 to check if the treatment is safe and tolerable, and to see if it can help control the disease. KSV01 uses a modified virus to deliver genetic instructions to the patient's own cells to fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KSV01 injection (a gene therapy using a modified virus to target cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong: This is a very early phase 1 trial with only 30 people, so it's too soon to know if it works. There are risks like severe immune reactions or nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-ALL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-ALL

Contacts and locations

Locations

First Affiliated Hospital of Zhejiang University
RECRUITING

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.